Current understanding of sodium-glucose transporter 2 inhibitors in cardiovascular-kidney-metabolic syndrome
Abstract
Cardiovascular-kidney-metabolic (CKM) syndrome is a recently defined clinical entity that encompasses cardiovascular disease (CVD), chronic kidney disease (CKD) and metabolic disorders. It has emerged as a growing public health concern that adversely affects the quality of life and imposes a substantial burden on human health. Sodium-glucose cotransporter 2 inhibitor (SGLT-2i) is a novel class of oral hypoglycemic agent with novel insulin-independent mechanism. In the last decade, published studies highlight its substantial effects on renal and cardiovascular outcomes. SGLT-2i is recommended for patients with stages 2-4 CKM syndrome, particularly those with CKD or diabetes to delay disease progression, and improve long-term clinical outcomes. This review comprehensively summarizes the current clinical evidence and elucidates the underlying mechanisms of SGLT-2i in CKM syndrome. Glycosuria and natriuresis, the primary effects of SGLT2 inhibition, play a pivotal role in improving glycemic control, reducing body weight, and lowering blood pressure. These initial effects trigger a cascade of downstream mechanisms: hemodynamic optimization via interstitial fluid reduction, enhanced cardiac efficiency through ketogenesis, and attenuation of inflammation and oxidative stress. Additional systemic benefits include increased fatty acid utilization, reduced hyperuricemia and stimulated erythropoiesis, thereby generating a network of interrelated therapeutic benefits in CKM syndrome.…
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.